| Name | Title | Contact Details |
|---|
Senda Biosciences, Inc. is uniquely positioned to transform human health by harnessing millions of years of evolution to program targeted, potent and tunable medicines. Nature has provided the codes to program human cells – both within the cell (mRNA), and, remarkably, to the cell - using what surrounds it. The trillions of non-human cells in the human ecosystem have evolved natural nanoparticles that precisely shuttle biomolecules into human cells, providing the missing pieces to fully unlock programmable medicines. Senda`s proprietary platform includes the first-ever atlas of nature-derived programmable systems at the molecular level and across all kingdoms of life – accessing the entire code provided by nature required to program cells. With this platform, Senda is developing a new class of SendRNA™ medicines. The unique properties of these medicines create new frontiers for mRNA therapeutics and vaccines for infectious, genetic, autoimmune, and metabolic diseases and oncology indications – with further potential to transform the gene editing and protein-based therapy landscapes as well. Based in Cambridge, MA, Senda was founded by Flagship Pioneering.
Sonitus Medical Inc. is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.
Rakuten Medical, Inc. is a global clinical stage biotechnology company developing and commercializing precision, cell-targeting investigational therapies on its IlluminoxTM platform, which, in pre-clinical studies have been shown to induce rapid and selective cell killing and tumor necrosis. Outside of Japan, Illuminox therapies have not yet been approved as safe or effective by any regulatory authority. The company`s first drug developed on the Illuminox platform, ASP-1929, has received approval from the Japanese Ministry of Health, Labour, and Welfare, and is currently the subject of a global phase 3 clinical trial for recurrent head and neck cancer. Rakuten Medical is committed to its mission to conquer cancer and aims to realize a society where cancer patients can lead fulfilling lives. The company has 6 locations in 5 countries, including the United States, where it is headquartered, Japan, the Netherlands, Taiwan, and Switzerland.
Metavention is a venture-backed medical device company founded in 2012 that is developing a novel glucose control therapy for patients with type 2 diabetes. Metabolic Neuromodulation Therapy (MNT) is a simple cardiovascular procedure intended to modulate sympathetic nervous system activity in patients with Type 2 diabetes for the purpose of lowering blood glucose levels. MNT was developed based on published scientific data and extensive animal studies suggesting a link between elevated sympathetic nerve activity in the metabolic system and increased levels of blood glucose. MNT is currently being studied in human clinical trials and represents a potentially important new treatment option for patients with Type 2 Diabetes.
Criada em 1977, são mais de quatro décadas de uma história construída com qualidade, acessibilidade e inovação, sempre com o foco no bem-estar da população brasileira. Sobre a Cimed: Somos uma das maiores farmacêuticas do país. Com mais de 40 anos de história, uma das poucas empresas do setor que permanece totalmente brasileira e independente até hoje. São mais de 600 produtos no catálogo e uma distribuição nacional para mais de 60 mil pontos de vendas. Além disso, a Cimed é líder em todos os setores em que atua. Temos nosso complexo fabril em Pouso Alegre (MG), o centro de distribuição central e a gráfica em São Sebastião da Bela Vista (MG), além de contar com 25 centros de distribuição espalhados pelo país. Com sede administrativa em São Paulo, são cerca de 5 mil colaboradores em todo Brasil. Somos, também, apoiadores do esporte nacional, patrocinando a Confederação Brasileira de Futebol. Projeto +: Mais de 280 mil m², esse é o tamanho do terreno da nova fábrica de sólidos orais da Cimed em Pouso Alegre, no Sul de Minas Gerais, a ser finalizada até 2022. A nova unidade terá aproximadamente 44 mil m² de área construída, fazendo com que a capacidade produtiva da área de sólidos passe de 28 milhões para 40 milhões comprimidos por mês, podendo chegar a 60 milhões. Pesquisa e Desenvolvimento: A Cimed é uma das poucas empresas do setor a ter o seu próprio centro de bioequivalência e a única a realizar todas as etapas de estudo necessárias para o registro de medicamentos genéricos e similares (clínica, analítica e estatística). Tudo isso é feito no Instituto Claudia Marques de Pesquisa e Desenvolvimento (ICM P&D), criado em 2004. Nossos números - Mais de 5 mil colaboradores - Mais de 60 mil pontos de venda - Presentes em mais de 90% das farmácias brasileiras - Cerca de 600 produtos no portfólio